Microbot Medical Inc has announced the launch of its LIBERTY robotic system, which has been adopted by Emory University Hospital for peripheral vascular procedures. This marks a significant milestone in the company's efforts to enhance patient care through innovative technology.
The LIBERTY system is the first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions. It aims to improve procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing the quality of care provided to patients.
Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology conference in April 2026, which is expected to accelerate market adoption and drive growth in the medical robotics sector.
Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 8.75 USD with a low forecast of 5.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 8.75 USD with a low forecast of 5.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.900
Low
5.50
Averages
8.75
High
12.00
Current: 1.900
Low
5.50
Averages
8.75
High
12.00
Roth Capital
Kyle Bauser
Buy
initiated
$5.50
2025-12-03
Reason
Roth Capital
Kyle Bauser
Price Target
$5.50
AI Analysis
2025-12-03
initiated
Buy
Reason
Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$9 -> $12
2025-09-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$9 -> $12
2025-09-11
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Microbot Medical to $12 from $9 and keeps a Buy rating on the shares after the FDA granted 510(k) clearance for the company's Liberty System. This is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, the analyst tells investors in a research note. The firm says the initial addressable market comprises 2.5M peripheral endovascular procedures annually in the U.S.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MBOT
Unlock Now
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$9
2025-04-10
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$9
2025-04-10
Reiterates
Strong Buy
Reason
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
